Physician profile
Larry R Smith
NPI 1619953569
$1,834.08
in general payments reported to CMS, 2019-2025
21 companies · $651 in 2025
The $651 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $141 · 2021: $13.20 · 2024: $592 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,209 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,208.89 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $361.88 | 2019-2025 | |
| Pfizer INC. | $278.47 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $181.26 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $111.95 | 2019-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $106.32 | 2024-2025 | Cuvitru, Takhzyro |
| Novartis Pharmaceuticals Corporation | $89.54 | 2019-2025 | |
| Glaxosmithkline, LLC. | $88.00 | 2024-2025 | Nucala |
| Pharming Healthcare, INC. | $72.69 | 2024-2025 | Ruconest |
| Amgen INC. | $68.52 | 2024-2025 | Tezspire |
| Galderma Laboratories, L.P. | $61.60 | 2024-2025 | Nemluvio |
| Ars Pharmaceuticals Operations, INC. | $60.00 | 2025 | Neffy |
| Octapharma USA, INC. | $49.32 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $46.23 | 2024 | Tezspire, Fasenra, Airsupra |
| Kedrion Biopharma, INC. | $45.43 | 2025 | Koate, Kedrab, Gammaked |
| Biosense Webster, INC. | $44.88 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $38.85 | 2024 | Auvi-Q |
| Novo Nordisk INC | $35.94 | 2019 | |
| Optinose US, INC. | $29.95 | 2019-2024 | |
| Blueprint Medicines Corporation | $27.38 | 2024 | Ayvakit |
| Dermavant Sciences, INC. | $23.88 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.